Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01715818 · ClinicalTrials.gov registry record · Phase 3
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,999
- Enrollment target
NCT01715818: Completed Phase 3 study, sponsored by Hoffmann-La Roche.
NCT01715818 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 1,999 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (159% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01715818, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,999 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled, parallel group, multicenter study will evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with stable cardiovascular disease and glucose abnormalities. Patients will be randomized 1:1 to receive either aleglitazar 150 mcg orally daily or matching placebo.
Interventions
- DRUG Placebo
- DRUG aleglitazar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,999 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
What the finished NCT01715818 record still lists
NCT01715818 is an interventional study that assigns participants to a tested intervention. Its 1,999 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (159% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01715818 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01715818 about?
NCT01715818 is a clinical study titled "A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities". This randomized, double-blind, placebo-controlled, parallel group, multicenter study will evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with stable cardiovascular disease and glucose abnormalities. Patients will be randomized 1:1 to receive either aleglitazar 150 mc...
What is the current status of trial NCT01715818?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,999 participants. The study started on 2012-12. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01715818?
The interventions under investigation include: Placebo (DRUG), aleglitazar (DRUG).
Who is sponsoring clinical trial NCT01715818?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01715818's enrollment target sits among peer trials
1,999 106th of 2000 higher than 1,895 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia